Biopharmaceutical Contract Manufacturing Market: Opportunities, Demand and Forecasts, 2017-2027

A new study by FMI titled ‘Biopharmaceutical Contract Manufacturing Market: Global Industry Analysis 2012–2016 and Opportunity Assessment 2017–2027’, has listed out the key points being considered by Biopharmaceutical contract manufacturing companies to emerge and stay sustainably profitable in the long run. The North American Biopharmaceutical contract manufacturing market is expected to expand at a CAGR of close to 10%, and is expected to remain as a main sink market for revenues, as most of the biopharmaceutical contract manufacturing facilities are located in this region. Europe is expected to remain as the main source market for biopharmaceutical contract manufacturing services. However, with the increasing demand and availability of large sterile spaces required for biopharmaceutical contract manufacturing in countries such as China, the biopharmaceutical contract manufacturing market is witnessing a move to Asia, to countries such as China and South Korea.

The report finds that Biopharmaceutical contract manufacturing capacity is tight across the industry, regardless of the location. Globally, biopharma companies have spent over US$ 50 Bn in just the past five years on new plants and equipment. Much of that has been in tax havens like Ireland and Singapore, and in emerging markets. About a quarter of the projects have been in the U.S. There just aren’t enough facilities, and those that are available are too old for modern drugs. It takes nearly four years to design, build, and qualify a new plant. Large-scale plants can cost between US$ 1 Bn and US$ 2 Bn. Patheon’s recent acquisition of Roche’s small facility in biopharmaceutical contract manufacturing sector was attractive because it was inexpensive, but is far from the norm. Much of the ongoing capacity expansion in the biopharmaceutical contract manufacturing industry is customer-funded.

A Sample of this Report is Available upon Request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-2982 

Biosimilar and biologics manufacturing are presenting strong growth opportunities for biopharmaceutical contract manufacturing organizations. The global biopharmaceutical contract manufacturing market is in a state of large consolidation, as participants in the biopharmaceutical contract manufacturing market look to inorganic growth strategies to offer integrated solutions to customers. For instance, leading players in biopharmaceutical contract manufacturing market – Patheon, Catalent, and AMRI have acquired IRIX Pharmaceuticals, Pharmatek, and Euticals, respectively. These biopharmaceutical contract manufacturing companies have been aggressive in expanding their products/services/capabilities through strategic alliances. Similarly, Aenova maintained its market position in the biopharmaceutical contract manufacturing market after the acquisition of Haupt Pharma AG, and by selling its Temmler business in 2015. Both, biopharmaceutical contract manufacturing companies – Fareva and Famar have successfully adopted an integration strategy of acquiring manufacturing facilities in Europe from large pharmaceutical companies.

Reinventing the European advanced therapies sector may fuel outsourcing activities to biopharmaceutical contract manufacturing players in the region. The next generation therapy market is driven by biological treatment options. These biologics demand more research and clinical trials, and hence, to reduce the cost, most research activities are outsourced to biopharmaceutical contract manufacturing players. The region is richly endowed with venture capitalists, which makes the availability of funding easier for biopharmaceutical contract manufacturing organizations. Potential margins for biopharmaceutical contract manufacturing companies are better in Europe as compared to the U.S. Factors noted by customers while approaching a biopharmaceutical contract manufacturing company are various. As per a NICE survey, a biopharmaceutical contract manufacturing company is selected based on location, quality of service, cGMP compliance, specific expertise in therapeutic area of focus, reputation and area of expertise, and infrastructure.

The top activity outsourced to biopharmaceutical contract manufacturing companies is analytical testing, followed by toxicity testing and fill/finish operations. Dominant outsourcing activities across the biopharmaceutical sector are restricted to services where a high degree of specialization may be required. While outsourcing to biopharmaceutical contract manufacturing companies can address a host of limitations, it comes with its own set of problems – protecting intellectual property rights, effectively handling cross-contamination issues, and complying with quality standards.

Rising focus on cost-effective biopharmaceutical contract manufacturing and the popularity of biosimilar added with the existence of patent cliff of blockbuster biologic drugs in the near future is expected to boost the growth of the biopharmaceutical contract manufacturing market. Big biopharmaceutical companies focusing on reduction in operating costs through the outsourcing of R&D and commercialization of biologic drugs to biopharmaceutical contract manufacturing companies could also increase the growth of the biopharmaceutical contract manufacturing market during the forecast period. However, complex manufacturing guidelines & regulatory processes, limited capacity for large-volume biopharmaceuticals, and high investments requirement to establish a biopharmaceutical contract manufacturing facility will continue to pose challenges to widespread adoption of outsourcing services in biopharmaceutical contract manufacturing market.

Read Comprehensive Overview with Methodology of Report @ https://www.futuremarketinsights.com/askus/rep-gb-2982 

Some of the key biopharmaceutical contract manufacturing companies analyzed in this report titled Biopharmaceutical contract manufacturing market include Lonza Group Ag, Baxter Healthcare Corporation, Samsung Biologics Co., Ltd., Fujifilm Diosynth Biotechnologies, Boehringer Ingelheim GmbH, Patheon N.V., Rentschler Biotechnologie GmbH, Biomeva GmbH, ProBioGen AG, Cytovance Biologics Inc, Kbi Biopharma Inc, WuXi Biologics (Cayman) Inc., Abzena Plc, Vetter Pharma International GmbH, Sandoz International GmbH, Catalent Inc, and AbbVie Contract Manufacturing.

Knee Reconstruction Market to Register Substantial Expansion by 2022

Knee reconstruction is a surgical procedure that includes the relocation of ACL or anterior cruciate ligament which stabilizes the knee. In case of tear of this major knee component, it might cause the knee to give up during any kind of physical movement. Aging population is rising which experiences knee problems such as osteoarthritis or even rheumatoid arthritis. This has triggered the demand for knee reconstruction on a significant scale. The technological advancements in medical science has introduced minimally invasive techniques which have enhanced the knee reconstruction procedure with increased precision, reduced complications, reduced time of surgery and enhanced accuracy. Various knee reconstruction devices are available, such as cementless implants, partial implants, cemented implants and revision implants which are widely applied in knee reconstruction surgeries. The improvisation and innovation of tools for knee surgeries have increased the demand for knee reconstruction surgeries, thereby showing a positive influence over the global knee reconstruction devices market.

The global knee reconstruction devices market is expected to grow at a robust CAGR during the assessment period 2017 to 2022, and is anticipated to be valued at US$9.4 Bn by 2022 end.

A Sample of this Report is Available upon Request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-4878

6 Forecast Highlights on Global Knee Reconstruction Devices Market

• North America region poised to dominate the global knee reconstruction devices market as it reflects high lucrativeness for the market growth during the 2017-2022 period and is expected to grow at a CAGR of 6.1%. Asia Pacific excluding Japan (APEJ) shows high potential of growth in the global knee reconstruction devices market
• Cementless implants and partial implants segments by product type grow at a similar growth rate, however, cementless implants segment possesses high market share as of 2017 as compared to partial implants segment
• Cemented implants by product type dominate the global market with respect to growth rate as well as market share by revenue throughout the 2017-2022 period and this segment is also expected to experience a high gain in the BPS the 2022 end. Cemented implants segment is anticipated to reflect a robust CAGR of 6.4%
• Orthopaedic clinics segment by end user reflect highest growth rate during the period of assessment 2017-2022 and is growing at a huge CAGR of 7.1%
• Hospitals segment by end user dominate the global market in terms of revenue, however, compared to orthopaedic clinics and ASCs segments, show low growth rate
• Trauma segment by indication is poised to be the fastest growing segment and reflects a CAGR of 6.5% during the assessment period. Osteoarthritis segment by indication dominates the market with respect to higher revenue share in 2017 and is more likely to continue dominating the market in the coming years

Request Report for Table of Contents @ https://www.futuremarketinsights.com/askus/rep-gb-4878

The report has also profiled key leading players in the global knee reconstruction devices market, which would remain active through 2022. These include players like Tornier Inc., Japan Medical Dynamic Marketing, DJO Global, Exactech Inc., Arthrex Inc., United Orthopedic Corporation, Corin, Smith & Nephew, DePuy Synthes, Stryker Corporation and Zimmer, Inc.

Soft Tissue Repair Market is Set to Experience Revolutionary Growth by 2022

A new report by Future Market Insights (FMI) anticipates the global soft tissue repair market to exhibit a steady 5.5% CAGR throughout the forecast period (2017-2022). The global market for soft tissue repair is expected to account for over US$ 15,000 Mn revenues by 2022-end.

Advancements in Products such as Bioabsorbable Soft Tissue Screws to Propel Growth of the Market

A number of technological advancements and innovations have been observed in orthopedic connective tissue repair procedures. Novel advances, for instance – the innovative surgical techniques, are being made in the procedures associated with anterior cruciate ligament (ACL) reconstruction, in a bid to make the process more effective. Global leaders, including Zimmer Biomet and NORAKER, have been developing new bioabsorbable soft tissue screws over the past few years. Leading market players have also been focusing on development of the mesh with biological products, which would act as a replacement for human allograft. An example of this is development of EZ Derm by MoInlycke Health Care, utilized as dressing for wounds using wires and pins independently, or together, with various other internal fixation devices. These devices are utilized for surgeries pertaining to hip replacement and spine.

A Sample of this Report is Available upon Request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-4931

People across the globe are becoming aware of development, promotion, and commercialization of the advanced platelet-rich plasma devices, used for musculoskeletal disorders. In addition, there is a surge in awareness about skeletally immature patients to have a high risk of tear in the connective tissue and ligaments. These factors might positively impact global demand for soft tissue repair in the near future.

Sports-related Injuries- A Major Factor Driving the Market Growth

A major factor affecting demand for soft tissue repair is injuries related to sports. Athletes usually suffer from ACL tear during the game, or while performing other physical activities. Moreover, increasing aging population is also expected to play an imperative role in growth of the market. With aging, substantial changes are observed in skeletal and neuromuscular systems, which in turn leads towards ACL tear, weak ligaments and arthritis. Prevalence of obesity in geriatric population is directly increasing risk of degenerative bone diseases, such as osteoporosis and osteoarthritis. The aforementioned factors are further expected to increase demand for soft tissue repair procedures.

In contrast, high prices associated with soft tissue repair procedures, lack of awareness in population across underdeveloped and remote regions, and unfavorable reimbursement policies are factors which will impede demand for soft tissue repair procedures in the near future.

APEJ to Witness a Significant Expansion in the Market

The soft tissue repair market in Asia-Pacific excluding Japan (APEJ) is expected to witness a significant growth, with revenues poised to surpass US$ 3,000 Mn by 2022-end. Growth of the market in APEJ can be primarily attributed to increasing purchasing power of population, and rising prevalence of musculoskeletal disorders in countries such as India and China. In addition, North America is expected to remain the most attractive market for soft tissue repair, owing to the hike in healthcare expenditure in this region.

Based on product, sales of laparoscopic instruments, and synthetic mesh are expected to collectively account for over one-third revenue share of the market during the forecast period. Sales of synthetic mesh and laparoscopic instruments will register similar CAGRs through 2022.

Orthopedic Application of Soft Tissue repair to Account for Largest Revenue Share

Orthopedic application of soft tissue repair are expected to account for the largest revenue share of the market during 2017 to 2022, followed by skin repair application. In addition, revenues from orthopedic and skin repair application of soft tissue repair are expected to collectively account for over US$ 7,000 Mn by 2022-end.

Accounting for around two-third revenue share of the market, hospitals are expected to remain the most lucrative end-users in the global market for soft tissue repair. Revenues from hospitals in the market are expected to reach approximately US$ 10,000 Mn by 2022-end.

Request Report for Table of Contents @ https://www.futuremarketinsights.com/reports/sample/REP-GB-4931

Key players profiled by the FMI’s report, who are actively operating in the global soft tissue repair market, include Wright Medical Group N.V., Integra LifeScience Corporation, Medtronic Plc., CONMED Corporation, C. R. Bard, Inc., Braun Melsungen AG, Smith & Nephew, DePuy Synthes, Stryker Corporation, Zimmer Biomet Holdings, Inc., and Arthrex Inc.

Herbal Medicinal Products Market to Record Sturdy Growth by 2027

The worldwide herbal medicinal products market is foreseen to develop reliably. This market is required to indicate noteworthy development in the Asia Pacific locale amid the estimate time frame i.e., in the vicinity of 2017 and 2027. For the further improvement of the market, makers need to put more in innovative work of the products and increment their item portfolio. Association and mergers are similarly essential for makers to manage in the worldwide herbal medicinal products market. These two components are relied upon to build the item portfolio as well as have the capacity to enable organizations to accomplish a solid market nearness over the globe. According to a recent report by Future Market Insights (FMI), with hearty CAGR of 7.6% amid the anticipated period, the worldwide market for herbal medicinal products is required to be esteemed at somewhat more than US$ 130 Bn in 2017.

A Sample of this Report is Available upon Request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-2722

Increase in Demand for Green Label Products to Propel the Global Market

Expanding customer interest for green label products is bringing about makers moving from specialty dispersion channels to standard mass retailers. In addition, general store chains are additionally extending item runs on their racks, which has brought about a sharp increment in shares of the herbal supplement items in the gone by years. High reception and fare of KAMPO solutions in Japan region is one of the explanation behind boosting the worldwide herbal medicinal products market. KAMPO solution is extremely mainstream and is broadly utilized as a part of Japan, which depends on conventional Chinese pharmaceutical in any case, altered as per the Japanese culture. Moreover, it is likewise received in Taiwan too with some alteration and sent out toward the Western locales. As indicated by the market review by WHO around 30% or more of the aggregate OTC medications that are for sale in Japan was readied utilizing organic products.

Ayurvedic Pharmaceuticals Segment to Account for Major Amount of Shares in the Market

Ayurvedic pharmaceuticals is required to be one of the most flourishing among all item sort fragment of herbal medicinal products market, including attractive index figure of 2.3. Besides, with over 55% income share, the Ayurvedic pharmaceuticals portion is probably going to be evaluated  to be around US$ 75 bn in year 2017, extending at a CAGR of 6.6%. In regions, for example, North America, the herbal meds products are viewed as/sold as dietary supplements or nutraceuticals with wellbeing claims, which is pre-affirmed by Food and Drug Administration (FDA) under Dietary Supplements Health and Education Act. The FDA controls for these products are less stringent when contrasted with the customary solutions. Accordingly, the great direction for herbals drugs especially in North America helps the improvement of the worldwide herbal prescriptions market. Expanding geriatric populace is another factor which is boosting the development of the worldwide herbal medicinal products market. The maturing populace in the nations, for example, Brazil and Mexico is equivalent to the European and North America nations. This populace utilize dietary supplements which powers the offer of herbal medicinal products.

Rise in Number of Patients Suffering from Join Pain to Fuel the Market Demand

Expanding number of individuals experiencing joint pain inclines toward normal strategies for treatment to remember the side effects caused by joint pain. Growing inclination towards regular cures gives great development chances to the players in basic oil industry sooner rather than later. Expanding interest for herbal supplements products is making open doors for players in the worldwide herbal supplements market to grow in various area through sending out their products Homeopathy has turned into an inexorably imperative component in the worldwide medicinal framework. The homeopathic cures have accomplished driving positions in various OTC classes. The online deals or web based business circulation channel has seen emotional increment in herbal medicinal products market in recent few years.

Read Comprehensive Overview with Methodology of Report  @ https://www.futuremarketinsights.com/askus/rep-gb-2722

Sanofi-Aventis Healthcare PTY Ltd., Nutraceutical Corporation, Himalaya Global Holdings Ltd., Integria Healthcare, Young Living Essential Oils, Blackmores Limited, Arkopharma SA, STADA Arzneimittel AG, Boiron Group, and MOUNTAIN ROSE HERBS are some of the key players reigning the global market.

Allergy Diagnostics Market Rugged Expansion Foreseen by 2022

The global market for allergy diagnostics has been forecast to account for over US$ 4,000 Mn revenues by 2022-end, according to a latest research by Future Market Insights (FMI). The report further projects the market to exhibit an impressive CAGR of nearly 10% through 2022.

Urban & Western Lifestyles Leading toward Susceptibility to Allergic Disorders

A key theory gaining popularity in the global allergy diagnostics market is “hygiene hypothesis”. According to the hypothesis, absence of exposure to microorganisms & infectious agents in early childhood is likely to increase proneness of individuals to allergies, refraining the essential development of their immune system. The urban and western lifestyles of people have made them more susceptible to allergic diseases, as they have limited exposure to infectious agents during their childhood. Genetic factors and surging pollution levels are some major factors adding to the prevalence of allergic disorders. Introduction of advanced technologies and rapid growth in healthcare expenditure will play a major role in reducing impact of aforementioned factors. However, stricter government policies and regulations associated with drugs and therapies, and huge capital investment required for development of these drugs will remain as challenges for organisations operating in the market.

A Sample of this Report is Available upon Request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-4959

Leading Market Players focusing on Revolutionizing Healthcare Sector

Several governments around the world are supporting development of vaccines and therapies associated with allergic diseases through investments in research and development activities related to allergy diagnostics. In addition, leading market players are focusing on revolutionizing and optimization of healthcare sector. A key strategy adopted by these players is collaboration with predominant organizations. For example – in 2016, Quest Diagnostics collaborated with AncestryDNA, in a bid to cater soaring demand from consumers for genetic tests, given the genetics’ role in development of allergies. The surge in incidences of allergies such as asthma, allergic rhinitis, sinusitis, and food allergy, are driving demand for their diagnostics over the recent past. According to WHO, number of patients with asthma is likely to surpass 400 Mn by 2025-end. Moreover, statistics offered by American Academy of Allergy, Asthma, & Immunology depict around 15% of population worldwide to be suffering from allergic rhinitis worldwide annually.

Key Research Findings from FMI’s Report on Global Allergy Diagnostics Market

• Diagnostic laboratories will remain sought-after among patients for allergy diagnostics, with revenues projected to account for over 40% revenue share of the market in 2017. However, diagnostic laboratories will observe a decline in their market share between 2017 and 2022.
• The allergy diagnostics market in Asia-Pacific excluding Japan (APEJ) is projected to expand at a relatively higher CAGR through 2022. This can be mainly attributed to a relatively higher prevalence of allergic disorders, especially in growing older population in the region, along with rising disposable income, and surging developments in healthcare infrastructures. In addition the market in Japan is estimated to create an absolute $ opportunity of approximately US$ 150 Mn between 2017 and 2022.
• Based on allergen type, revenues from diagnosis of allergies caused by food allergens are estimated to reach nearly US$ 1,300 Mn by 2022-end.
• On the basis of test type, in-vivo tests are expected to remain comparative less lucrative than in-vitro test for allergy diagnostics throughout the forecast period.
• Based on Product type, sales of consumables and instruments are projected to register the fastest expansion in the market through 2022. In terms of revenues, instruments are estimated to account for a comparatively larger market share than consumables over the forecast period. In contrast, services will account for the lowest share of the market, in terms of revenues, through 2022.

Read Comprehensive Overview with Methodology of Report @ https://www.futuremarketinsights.com/askus/rep-gb-4959

FMI’s report has offered a list of key players that are actively operating in the allergy diagnostics market, which include Thermo Fisher Scientific, Inc., Siemens Healthcare, Danaher Corporation, Hitachi Chemical Co., Ltd., HOB Biotech Group Co, Biomérieux SA, Stallergenes Greer, R-Biopharm AG, Hycor Biomedical Inc., and Lincoln Diagnostics, Inc.

Multiplex Biomarker Imaging Market Attractive Market Opportunities in the by 2027

A new report published by Future Market Insights titled “Multiplex Biomarker Imaging Market: Global Industry Analysis (2012 – 2016) and Opportunity Assessment (2017 – 2027)” studies the performance of the global multiplex biomarker imaging market over a ten year assessment period from 2017 to 2027. The report presents the value forecast of the global multiplex biomarker imaging market and provides key insights into the factors driving market growth as well as the factors restricting market growth. The estimates point to a revenue growth from about US$ 270 Mn in 2017 to nearly US$ 843 Mn by 2027 end, resulting in a CAGR of 12% over the forecast period.

A Sample of this Report is Available upon Request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-3526

Global Multiplex Biomarker Imaging Market: Segmentation and Forecast

The global multiplex biomarker imaging market is segmented on the basis of component type, imaging technique, application and end-user.

• The instrument segment is estimated to be valued at US$ 200.6 Mn in the year 2017 and is poised to reach a value of US$ 620.4 Mn at the end of the year 2027 and exhibit a CAGR of 12% during the period of assessment.
• The software segment is estimated to be valued at US$ 41.2 Mn in the year 2017 and is slated to reach a value of US$ 133.2 Mn at the end of the year 2027 and exhibit a CAGR of 12.5% during the period of assessment.
• The IHC Assay segment is estimated to be valued at US$ 177.9 Mn in the year 2017 and is slated to reach a value of US$ 557.4 Mn at the end of the year 2027 and exhibit a CAGR of 12.1% during the period of assessment.
• The FISH Assay segment is estimated to be valued at US$ 59.4 Mn in the year 2017 and is poised to reach a value of US$ 179.4 Mn at the end of the year 2027 and exhibit a CAGR of 11.7% during the period of assessment.
• The research segment is estimated to be valued at US$ 238.6 Mn in the year 2017 and is poised to reach a value of US$ 740.5 Mn at the end of the year 2027 and exhibit a CAGR of 12% during the period of assessment.
• The translational laboratories segment is estimated to be valued at US$ 4 Mn in the year 2017 and is slated to touch a value of US$ 418.2 Mn at the end of the year 2027 and exhibit a CAGR of 12.8% during the period of assessment.

Global Multiplex Biomarker Imaging Market: Regional Forecast

Future Market Insights tracks the performance of the global multiplex biomarker imaging market across the key geographies of North America, Latin America, Eastern Europe, Western Europe, Asia Pacific excluding Japan, Japan, and Middle East and Africa. As per the forecast of Future Market Insights, the North America multiplex biomarker imaging market is estimated to be valued at US$ 152.4 Mn in the year 2017 and is slated to touch a value of US$ 501.4 Mn at the end of the year 2027 and exhibit a CAGR of 12.6% during the assessment period. The Western Europe multiplex biomarker imaging market is estimated to be valued at US$ 64.7 Mn in the year 2017 and is poised to touch a value of US$ 208.6 Mn at the end of the year 2027 and exhibit a CAGR of 12.4% during the period of assessment.

Read Comprehensive Overview with Methodology of Report @ https://www.futuremarketinsights.com/askus/rep-gb-3526

Global Multiplex Biomarker Imaging Market: Vendor Insights

The report has included some of the key players operating in the global multiplex biomarker imaging market such as Perkin Elmer, Inc., Bio-rad Laboratories Inc., Thermo Fisher Scientific, Inc., Abcam plc., Merck KGaA, Illumina Inc., Leica Biosystems Nussloch GmbH, Ventana Medical Systems, Inc., Aushon BioSystems Ltd., MicroConstants, Inc. and ToposNomos Ltd. Leading manufacturer of Multiplex Biomarker Imaging are focusing on collaborations with laboratories and biopharmaceutical companies in order to expand sales presence. Other companies are focusing on targeting technologically advanced emerging economies such as Asia Pacific region with availability of sufficient capital base and skilled labour.

Animal Healthcare Market Healthy Pace throughout the Forecast during 2017 - 2027

According to a recently compiled study by Future Market Insights, the global animal model market will reflect an impressive CAGR through the forecast period, 2017 to 2026. Revenues from the global market for animal model are poised to surpass US$ 2,200 Mn by 2026-end.

Leveraging Animal Models offers Better Understanding of Different Diseases

Animals and human beings share a common biological as well as physiological structure. Animals possess shorter life cycle, however they have high genotype resemblance. It is simple and easy to control the animal environment as compared to the human beings. The animal models are increasingly being used in the biomedical research that helps to develop new treatment methods for various diseases. Leveraging animal models offers a better understanding of different diseases, along with the efficacy of drugs with regard to the diseases. Owing to these factors, demand for animal models has been witnessing a significant surge in the healthcare sector. Alternatives such as cell cultures, tissue cultures, and computer models are also available, however animal models are more preferred owing to the complexity of the living systems. This further makes animal models an effective choice for biomedical research.

To Learn More about This Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-3141 

Development of animal models, which are more predictive in being effective is an iterative process. However, progress is being made, with researchers applying new experimental approaches to elucidate the biology of specific diseases for the creating of new and efficient animal models. During the development of new drugs dedicated to complex diseases, researchers are being well advised for testing drugs in multiple animal models as well as in mouse strains with different genetic backgrounds. Researchers are also focusing on employing translational efficacy or pharmacodynamic biomarkers for linking efficacy observed in clinical results with pre-clinical analyses.

Key Takeaways from FMI’s Report on Global Animal Model Market

• North America is expected to remain the largest and fastest expanding market for animal model, with revenues estimated to surpass US$ 800 Mn by 2026-end. Between animal model markets in Asia-Pacific and Europe, the former will account for relatively larger revenue share, whereas the latter will expand at a comparatively higher CAGR through 2026. Although the market in South Korea will account for the lowest market revenue share, revenues are projected to expand at a relatively higher CAGR than those from the markets in Latin America and Middle East & Africa (MEA) through 2026.
• On the basis of species, revenues from rats and mice are projected to account for over two-fifth share of the market by 2026-end. Revenues from use of rats in animal models will expand at the highest CAGR in the market through 2026. In addition, revenues from use of cats and monkeys in animal models will rise at a nearly equal CAGR through 2026. Dogs and pigs are expected to remain the least lucrative species used in animal models during the forecast period.
• Contract research organizations (CROs) and biotechnology companies are anticipated to remain the fast expanding end-users of animal models. Revenues from these two end-users are collectively forecast to surpass US$ 850 Mn by 2026-end. In terms of revenues, academic & research institutions and pharmaceutical companies will continue to be dominant end-users in the global animal model market.
• Basic and applied research application of animal model will continue to register the fastest expansion through 2026. However, drug discovery/development will remain the most lucrative application of animal model.
• Key companies actively contributing to growth of the global animal model market include Transposagen Biopharmaceuticals, Inc., Envigo CRS SA, Crown Bioscience, Inc., Eurofins Scientific SE, Genoway SA, Taconic Biosciences, Inc., Trans Genic Inc, The Jackson Laboratory, Horizon Discovery Group plc, and Charles River Laboratories International, Inc.

Request Report for Table of Contents @ https://www.futuremarketinsights.com/askus/rep-gb-3141 

Molecular Imaging Market Likely to Emerge over a Period of 2017 - 2027

The global molecular imaging market is expected to witness robust growth during the forecast period. This growth is expected to be primarily driven by increasing demand for advanced integrated molecular imaging devices such as PET-CT and PET-MR from hospitals and diagnostics imaging centres. “Molecular Imaging Market: Global Industry Analysis (2012 –2016) and Opportunity Assessment (2017 – 2027),” is the newly published report by Future Market Insights which focuses on the key strategies such as acquisitions, mergers, expansion and product launchesadopted by the manufacturers and integrators in this market for technology transfer and to increase consumer base in different geographies. The global molecular imaging market is projected to register a CAGR of 7.5% in terms of value during the forecast period i.e. 2017–2027 and to be valued at US$ 6,445.8 Mn by 2027.

A Sample of this Report is Available upon Request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-724

Global Molecular Imaging Market: Drivers

Following are some of the factors which are contributing in the growth of the global molecular imaging market throughout the forecasted period.

• Advancements in the molecular imaging
• Favorable reimbursement for molecular imaging and treatment
• Increasing demand for molecular imaging and diagnosis
• Increasing incidences of ageing population’s MRI diagnostics
• Expanding application of integrated PET-CT and PET-MR devices
• Favorable government policies for startup companies
• Increasing Strategic Collaborations among key players
• Increasing reliance of physicians and radiologists on the technology

Global Molecular Imaging Market: Forecast by Modality Type

On the basis of modality type, the global molecular imaging market is segmented into- Positron Emission Tomography (PET), Positron Emission Tomography- Computed Tomography (PET-CT),

Positron Emission Tomography-Magnetic Resonance (PET-MR), Single Photon Emission, Computed Tomography (SPECT), Magnetic Resonance Spectroscopy, Molecular Ultrasound Imaging Software. The SPECT segment of modality type accounted for 23.3%market share in 2016, which is expected to decrease to 22.7% by 2027end. This segment is expected to accounts for large revenue contributionto the global molecular imaging market as compared to other segmentsover the forecast period. On the other hand PET-CT molecular imaging segment is expected to witness a significant rise in revenue share over the forecast period, owing to increasing awareness about the advantages of PET-CT integrated devices compared to stand alone molecular imaging devices.

Global Molecular Imaging Market: Forecast by End User

This segment consists of hospital, ambulatory surgical centre, and diagnostic imaging centre. Hospital segment is sub-segmented into 500 + beds, 200-499 beds, and less than 200 Beds.   Hospital segment dominated the global molecular imaging market in revenue terms in 2016, and the trend is projected to continue throughout the forecast period. Hospitals segment is expected to be the most lucrative among all end users, with attractiveness index of 1.8. This segment is expected to grab 58% revenue share in 2027.

Global Molecular Imaging Market: Forecast by Application

Application segment includes cardiology, oncology, gastrointestinal disorders, neurology disordersand others. In terms of value, oncology is the largest segment and is likely to be valued US$ 2,391.7 Mn in 2027. However, in terms of CAGR, neurological disorders segment is ahead with 8.4% Compound Annual Growth Rate at the end of the projected period. By market share index, this segment is expected to be the second largest in the global molecular imaging market.

Global Molecular Imaging Market: Forecast by Region

This report has covered seven regions such as North America, Latin America, Eastern Europe, Western Europe, APEJ, Japan, and MEA. APEJrepresents the most lucrative market, followed by MEA andNorth America. The APEJ molecular imaging market revenue is expected to expand at a significant CAGR of 8.6% in terms of value over the forecast period. The hospitals and diagnostics imaging centres in APEJ are expectedto witness comparatively significant growthdue to increasingdemand of advanced molecular imaging and developing medicalinfrastructure in the region.

Read Comprehensive Overview with Methodology of Report @ https://www.futuremarketinsights.com/askus/rep-gb-724

Global Molecular Imaging Market: Key Players

These are some of the key players in the global molecular imaging market- Hermes Medical Solutions, MIM Software Inc., Bruker Corporation, GE Company, Fujifilm Holdings Corp., Siemens AG, Koninklijke Philips N.V., Toshiba Medical System Corp., Hitachi Medical Corp.,Medisco Ltd., Positron Corporation, Esaote SpA, Carestream Health, Inc., Mirada Medical Limited.

Competent Cells Market Highly Favorable to the Growth Rate by 2022

A latest research study published by Future Market Insights (FMI) projects the global competent cells market to register an impressive 8.1% CAGR throughout the forecast period 2017 to 2022. The global market for competent cells is estimated to exceed US$ 2,000 Mn in revenues by 2022-end.

Competent Cells Available in the Market in Ready-to-use Formats

Preparations of competent cells, along with other methods of transformation, have been continuously improvised, since the development of E. coli’s artificial transformation with the help of electroporation and chemicals. Currently, various competent cells are available in the market in ready-to-use formats for propagating cloned plasmids in the experiments of molecular biology. These competent cells are prepared for different transformation procedures, genotypes, packaging, and transformation efficiencies.

With the advent of new technologies, several advancements have been witnessed in the molecular cloning research. Over the past few years, the recombinant proteins and molecular cloned products have experienced a robust commercial demand, thereby driving adoption of competent cells. However, adoption of competent cells is witnessing strong barriers on the back of increasing consolidation of the market, and huge cost of kits related to competent cells.

Request to View Sample of Research Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-5061 

North America will Continue to be Largest Market for Competent Cells

In terms of revenues, North America is anticipated to remain the largest market for competent cells, with sales estimated to exceed US$ 750 Mn in revenues by 2022-end. Huge investments in research and development activities associated with competent cells is driving the market in North America. In addition, the market in Europe is estimated to create an absolute $ opportunity of nearly US$ 200 Mn between 2017 and 2022.

On the basis of product type, although chemically competent cells will continue to be sought-after in the market, sales of electrocompetent cells are projected to register a relatively faster expansion through 2022. Growing demand for electrocompetent cells can be mainly attributed to their provision of high transformation efficiencies, making them suitable for several molecular biology applications, for example – construction of gene banks, or, generation of cDNA libraries. Revenues from sales of electrocompetent cells are projected to account for nearly one-third share of the market over the forecast period.

Academic Research Institutes to Remain Largest End-users of Competent Cells

Academic research institutes are anticipated to remain the largest end-users of competent cells throughout the forecast period. Sales of competent cells in academic research institutes are projected to exhibit an impressive expansion to account for nearly half revenue share of the market during 2017 to 2022. However, sales of competent cells in pharmaceutical & biotechnology companies are expected to register the fastest expansion through 2022. Contract research organisations are expected to be the least lucrative end-users of competent cells in the global market.

Competent cells are expected to find the largest application in cloning during 2017 to 2022. Governments across the globe are providing tremendous support and funding for research and development activities associated with cloning. Revenues from sales of competent cells for application in cloning are estimated to account for over half revenue share of the market during the forecast period. Sales of competent cells for application in protein expression are expected to register the highest CAGR through 2022.

Request Report for Table of Contents @ https://www.futuremarketinsights.com/askus/rep-gb-5061 

Leading Market Players focusing on Increasing their Product Portfolio

Global leading players in the competent cells market are focusing on increasing their product folio, in a bid to gain a competitive edge in the market. Key players listed in FMI’s report on the global competent cells market include Agilent Technologies Inc., Bio-Rad Laboratories Inc., Genescript Biotech Corporation, Illumina, Inc., Merck & Co. Inc., New England Biolabs Inc., OriGene Technologies, Inc., QIAGEN N.V., Thermo Fischer Scientific, Inc., and Zymo Research Corporation.

Neonatal Phototherapy Devices Market Rugged Expansion Foreseen by 2027

Neonatal jaundice is a major concern amongst new-borns and is a common cause of morbidity in the crucial first few months of life. Approx. 80% of preterm new-borns can suffer from neonatal jaundice making its effective treatment a critical health issue. Future Market Insights has conducted an exhaustive study on the neonatal phototherapy devices market in its upcoming report titled ‘Neonatal Phototherapy Devices Market: Global Industry Analysis 2012 – 2016 and Opportunity Assessment 2017 – 2027’. The neonatal phototherapy devices market is anticipated to witness a CAGR of 5.3% for the period 2017-2027 and grow to more than US$ 140 million by then.

Product Type – Traditional Phototherapy Commonly Preferred by Hospitals

Traditional phototherapy devices are the most commonly used product type in the neonatal phototherapy devices market on account of their relative affordability – especially relevant in emerging economies. Traditional phototherapy devices have an improved lifespan and can easily be attached to an incubator. The National Institute of Health found that almost 15 million babies are born premature around the world with significantly increasing figures over the past few decades. This is the surest sign that the need for foetal, neonatal, and prenatal care equipment will skyrocket in the future, benefiting the neonatal phototherapy devices market.

A Sample of this Report is Available upon Request @ https://www.futuremarketinsights.com/reports/sample/REP-GB-5064

The development of advanced technologies in North America and Western Europe should propel the neonatal phototherapy devices market with a strong demand for products such as LED phototherapy units. Traditional phototherapy devices are primarily used by hospitals as they are easy to install, simple to use, and durable. Furthermore, the height of the phototherapy lamp can be easily adjusted. A number of non-profit organisations and large players in the neonatal phototherapy devices market are collaborating on the development of cost-effective phototherapy units that can treat neonatal jaundice at the minimal cost in emerging economies.

Product Type – Phototherapy Beds Better Suited to Home Care Settings

The phototherapy bed market is predicted to record a CAGR of 5.6% over the forecast period. Phototherapy beds are lightweight and portable and help maintain the vital bond between mothers and their babies. Phototherapy beds are efficient, low-cost, simple to use, and perfect in either home care or nursery ward settings.

Product Type – Flexible Phototherapy Devices Offer the Best of Both Worlds

Flexible phototherapy devices, as their name suggests, mould their shape according to that of the baby and are available in a range of sizes in the neonatal phototherapy devices market. Flexible phototherapy devices offer an extremely soothing healing environment for a new-born baby without hampering the benefits of Kangaroo Care (Mother – child bonding). The flexible phototherapy lamps market is projected to cross a value of US$ 11 million in 2017 alone.

Region – APAC to Grab Maximum Attention in the Neonatal Phototherapy Devices Market

Emerging markets i.e. APAC, Latin America, and the MEA region account for the lion’s share of the global population and have half the neonatal phototherapy devices market to themselves. The APAC region spearheaded by China and India is making significant effort in trying to leverage the existing opportunities in the neonatal phototherapy devices market. Key stakeholders in the neonatal phototherapy devices market are focusing their energy on these regions because of the high birth rate and rising prevalence of diseases that thereby drives the APAC neonatal phototherapy devices market.

Competition Dashboard in the Neonatal Phototherapy Devices Market

The companies profiled by Future Market Insights in the neonatal phototherapy devices market report include Natus Medical Incorporated, General Electric Company, Ibis Medical Equipment and Systems, Atom Medical Corporation, Medela AG, D-Rev, Phoenix Medical Systems, Zhengzhou Dison Instrument And Meter, Fanem, Drägerwerk AG & Co., Novos Medical Systems, Weyer GmbH, BabyBloom Healthcare BV, Medical Technology Transfer and Services Asia, Koninklijke Philips N.V., and Medical Technology Transfer and Services Asia.

Request Report for Table of Contents @ https://www.futuremarketinsights.com/askus/rep-gb-5064 

Important Insights on the Neonatal Phototherapy Devices Market

Governments in several countries have begun programs that provide more facilities for new-born and childcare along with promotions through conferences and exhibitions. For e.g. – In African nations, communities have initiated programmes that have new-born health and safety as their primary objective.

Microscope Digital Cameras Market: Industry Trends and Developments 2017-2027

Valuable insights on the global scenario of microscope digital cameras have been presented systematically in a recently carried out research on microscope digital cameras market by Future market Insights in its new publication titled “Microscope Digital Cameras: Global Industry Analysis (2012-2016) and Opportunity Assessment (2017-2027)”. This research focusses on key players, trends, growth drivers, opportunities, developments and restraints across several key geographies of North America, Western Europe, Eastern Europe, Asia Pacific excluding Japan (APEJ), Latin America, Japan and Middle East and Africa (MEA). On the basis of a structured research process and taking into consideration the past and present scenario, forecasts are provided in the research report from the period 2017 to 2027, a ten year forecast model, across each and every segment of the market.

Request to View Sample of Research Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-3523 

Global Microscope Digital Cameras Market: Forecast Highlights

According to the insightful market survey on microscope digital cameras, the global microscope digital cameras market is anticipated to grow at a high pace to register a robust 9.2% CAGR during the assessment period. During the 2017-2027 period, the global market is estimated to reach a market evaluation of about US$ 1.2 Bn by the end of 2027.

Global Microscope Digital Cameras Market: Segmental Insights

Global microscope digital cameras market is segmented by product type (biological microscope cameras, industrial microscope cameras), by sensor type (CMOS, CCD), by mount type (C mount, eyepiece mount/ocular mount), by end user (hospitals, research laboratories, pharmaceutical and biotechnology industries, clinics) and by region.

• North America region shows high lucrativeness and is expected to dominate the global microscope digital cameras market during the forecast period with respect to high market valuation. This region is estimated to grow at a stellar growth rate to reach a valuation of about US$ 353.3 Mn by 2027 end. Japan region is expected to grow at the highest rate, a shade higher than North America to register a 10.3% CAGR throughout the forecast period
• Biological microscope cameras segment by product type, is projected to register a higher CAGR of 9.3% during the forecast period and is more likely to lead the global market by product type in terms of high market value
• By mount type, C mount segment shows high potential as it grows at a comparatively high rate to reach a 9.4% CAGR and is likely to show dominance over eyepiece mount/ ocular mount segment. The C mount segment shows a market value almost seven times that of the eyepiece mount/ ocular mount segment
• The CCD segment by sensor type is expected to lead the market with a high value share. The CMOS segment shows high growth rate to register a stellar CAGR of 11.3% throughout the assessment period
• By end user, research laboratories (clinical and non-clinical) segment dominates the global market with a valuation of about US$ 645.7 Mn in 2027, growing at a robust growth rate. With respect to growth rate, the pharmaceutical and biotechnology industries segment is projected to register the highest CAGR of 9.7% during the period of forecast 2017-2027

Global Microscope Digital Cameras Market: Dynamics

Various factors favour the growth of the global microscope digital cameras market and the impact of these factors changes from region to region. Diverse application of microscope imaging technology, rising preference for CMOS and CCD, increasing penetration of international players through mergers, growing partnerships for direct distribution, higher spending on academic research along with focus on digital pathology, emergence of digitalization in the life science research, rising demand for microscopy cameras in scientific applications, new product innovations and launches, advancements in microscope digital cameras and rising laboratory automation are supporting the growth of the global microscope digital cameras market. However, factors such as premium pricing limiting market penetration ability, limited manufacturing facilities for microscope cameras, high equipment cost and entry barriers for small players to enter the consolidated market are posing growth restraints to the growth of the global microscope digital cameras market.

Request Report for Table of Contents @ https://www.futuremarketinsights.com/askus/rep-gb-3523 

Global Microscope Digital Cameras Market: Competition Analysis

The global microscope digital cameras market has profiled key players such as Danaher Corporation, Nikon Corporation, Roper Technologies, Inc., Carl Zeiss AG, Olympus Corporation, Hamamatsu Photonics K.K, Basler AG, Guangzhou Micro-shot Technology Co., Ltd., BMS microscopes bv., and Euromex Microscopen bv.

Downstream Processing Market Size Projected to Rise Lucratively during 2017-2022

Downstream processing is used to manufacture antibiotics, antibodies, hormones, vaccines and also used for the production of industrial enzymes. In downstream processing, the purification and recovery of biosynthetic products is done that are derived from natural sources such as tissues of animals and plants. The growth of the downstream processing market is fuelled by the ever growing demand for biopharmaceuticals and increasing R&D spending on the development of such products. However, the high cost of the instruments involved in downstream processing and a dearth of skilled workforce is hampering the growth of this market.

Request to View Sample of Research Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-5070 

The global downstream processing market is slated to touch a value of about US$ 25,800 Mn in the year 2022 and display a robust CAGR during the assessment period.

4 Forecast Highlights on Global Downstream Processing Market

• As per the forecast of Future Market Insights, the filters product type segment is slated to touch a value of nearly US$ 5,700 Mn in the year 2022. This represents a robust CAGR during the assessment period of 2017-2022. The filters product type segment is estimated to account for more than one-fifth of the revenue share of the product type segment by the year 2017 and is forecasted to lose market share by 2022 over 2017.

• As per the forecast of Future Market Insights, the contract manufacturing organizations segment will reach a value of nearly US$ 5,500 Mn in the year 2017. This represents a robust CAGR growth during the forecast period. The contract manufacturing organizations segment is forecasted to account for more than one-third of the total revenue share of the end users segment by the end of the year 2017 and is expected to lose in market share by 2022 as compared with the year 2017.

• As per the forecast of Future Market Insights, the monoclonal antibody production segment is slated to reach a value of about US$ 8,300 Mn in 2022. The monoclonal antibody production segment is expected to gain market share by the end of the year 2022. The largest share is contributed by the North America region in the monoclonal antibody production segment.

• Future Market Insights forecasts the gel chromatography segment to exhibit a compound annual growth rate (CAGR) of nearly 15.0% from 2017 to 2022.

Request Report for Table of Contents @ https://www.futuremarketinsights.com/askus/rep-gb-5070 

The report has also included the profiles of some of the leading companies in the downstream processing market like Sartorius Aktiengesellschaft, Repligen Corporation, Merck & Co Inc., Thermo Fisher Scientific, Inc., Eppendorf AG, General Electric Company, Corning Incorporated, 3M Company, Lonza Group Ltd. and Danaher Corporation.